A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel

Pexidartinib (PLX3397) is a small molecule tyrosine kinase and colony-stimulating factor-1 inhibitor with FDA breakthrough therapy designation for tenosynovial giant-cell tumor, and currently under study in several other tumor types, including breast cancer, non-Hodgkin’s lymphoma, and glioblastoma....

Descripción completa

Detalles Bibliográficos
Autores principales: Piawah, Sorbarikor, Hyland, Colby, Umetsu, Sarah E., Esserman, Laura J., Rugo, Hope S., Chien, A. Jo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570645/
https://www.ncbi.nlm.nih.gov/pubmed/31240240
http://dx.doi.org/10.1038/s41523-019-0112-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570645/
https://www.ncbi.nlm.nih.gov/pubmed/31240240
http://dx.doi.org/10.1038/s41523-019-0112-z

Ejemplares similares